Table 1 A summary of the baseline demographics and disease characteristics of all enrolled pSS patients
pSS-non-ILD n=76 | pSS-ILD n=66 | P | |
|---|---|---|---|
Female, n(percentage) | 68 (89.5%) | 56 (84.8%) | 0.409 |
Age (years), mean ± SD | 55.36±8.51 | 60.83±8.58 | <0.001 |
Age at onset of pSS (years), mean ± SD | 50.03±8.83 | 55.41±8.41 | <0.001 |
Duration of pSS (months), median(range) | 60.00 (0.25, 240.00) | 52.00 (2.00, 276.00) | 0.492 |
ESSDAI, median(range) | 3.0 (0.0, 10.0) | 13.5 (6.0, 32.0) | <0.001 |
Clinical manifestation, n(percentage) | |||
Fever | 17 (22.4%) | 21 (31.8%) | 0.205 |
Cough | 19 (25.0%) | 44 (66.7%) | <0.001 |
Expectoration | 14 (18.4%) | 22 (33.3%) | 0.042 |
Anhelation | 11 (14.5%) | 24 (36.4%) | 0.003 |
Stethalgia | 0 (−) | 5 (7.6%) | 0.020 |
Haematocyanosis | 0 (−) | 7 (10.6%) | 0.004 |
Velcro rale | 3 (3.9%) | 24 (36.4%) | <0.001 |
Laboratory indicators, median(range) or n(percentage) | |||
WBC (×109/L) | 5.11 (1.56, 15.19) | 5.58 (1.66, 21.78) | 0.067 |
Hb (g/L) | 123 (46, 154) | 125 (4, 169) | 0.571 |
PLT (×109/L) | 215 (11, 511) | 203 (39, 759) | 0.713 |
LY (×109/L) | 1.63 (0.13, 3.98) | 1.55 (0.26, 3.58) | 0.286 |
ESR (mm/h) | 27 (1, 120) | 37 (2, 120) | 0.076 |
CRP (mg/L) | 3.6 (1.0, 138.0) | 4.3 (1.0, 114.0) | 0.053 |
IgG (g/L) | 14.3 (6.7, 56.1) | 15.9 (6.6, 48.2) | 0.732 |
IgA (g/L) | 2.7 (0.5, 13.8) | 3.1 (0.8, 13.8) | 0.197 |
IgM (g/L) | 1.0 (0.3, 11.7) | 1.3 (0.3, 22.0) | 0.224 |
C3 (g/L) | 0.76 (0.23, 1.48) | 0.78 (0.03, 1.49) | 0.486 |
C4 (g/L) | 0.18 (0.03, 0.37) | 0.19 (0.05, 2.34) | 0.496 |
Anti-ENA | 30 (39.5%) | 27 (42.2%) | 0.745 |
Anti-Sm | 1 (1.3%) | 5 (7.8%) | 0.059 |
Anti-SSA (60kD) | 31 (40.8%) | 35 (54.7%) | 0.101 |
Anti-SSB | 5 (6.6%) | 13 (20.3%) | 0.016 |
Anti-Ro52 | 18 (23.7%) | 37 (61.7%) | <0.001 |